Eric Rittenhouse, MD
Obstetrics & Gynecology · Honesdale, PANPI 1376520593
Payments from drug & device makers
Across 334 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$1K
- AbbVie$1K
- Astellas Pharma US Inc$923
- Pfizer$570
- Sage Therapeutics, LLC$324
- Sumitomo Pharma America, Inc.$257
- plus $2K from 35 others
What the payments were for
- Travel & lodging$5008%
- Food & beverage$5,62287%
- Education$3095%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 17 | $1,107 |
| AbbVie(2 entities) | 65 | $1,037 |
| Astellas Pharma US Inc | 63 | $923 |
| Pfizer | 33 | $570 |
| Sage Therapeutics, LLC | 18 | $324 |
| Sumitomo Pharma America, Inc. | 20 | $257 |
| Mayne Pharma Commercial LLC | 15 | $236 |
| Myovant Sciences Inc. | 11 | $174 |
| Organon | 13 | $163 |
| Daiichi Sankyo Inc. | 8 | $153 |
| Lilly USA, LLC | 2 | $146 |
| Femselect Inc. | 1 | $105 |
| Bayer | 5 | $103 |
| Mylan Pharmaceuticals Inc. | 4 | $96 |
| Therapeuticsmd, Inc. | 5 | $87 |
| Merck | 7 | $86 |
| Novo Nordisk | 4 | $81 |
| Millicent US Inc | 5 | $80 |
| Shield Therapeutics Inc | 4 | $78 |
| Boston Scientific | 3 | $74 |
| Exeltis, USA Inc. | 3 | $49 |
| Amgen | 3 | $49 |
| AstraZeneca | 2 | $47 |
| Johnson & Johnson | 2 | $39 |
| Hologic Sales And Service, LLC | 2 | $39 |
| Medtronic | 2 | $36 |
| Minerva Surgical, Inc | 2 | $34 |
| Smith+Nephew | 2 | $27 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Aspira Women's Health Inc | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Urovant Sciences Inc | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Teleflex LLC | 1 | $18 |
| Agile Therapeutics, Inc. | 1 | $18 |
| Mission Pharmacal Company | 1 | $17 |
| Alydia Health | 1 | $16 |
| Olympus America Inc. | 1 | $15 |
| Avion Pharmaceuticals | 1 | $13 |
| Medicem Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics r-SNM System$778
- Bulkamid$609
- ZEPBOUND$125
- EnPlace$105
How this compares
$6,431 in reported general payments places this provider in the 90th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 73 | $70,496 |
| ElmironPentosan Polysulfate Sodium | 26 | $51,280 |
| GemtesaVibegron | 48 | $43,889 |
| PremarinEstrogens, Conjugated | 49 | $23,675 |
| PremproEstrogen,con/M-Progest Acet | 30 | $12,256 |
| Darifenacin ErDarifenacin Hydrobromide | 31 | $6,846 |
| Estradiol | 158 | $6,315 |
| Solifenacin Succinate | 49 | $2,749 |
| Oxybutynin Chloride ErOxybutynin Chloride | 84 | $2,088 |
| Tolterodine Tartrate ErTolterodine Tartrate | 17 | $1,809 |
| Clobetasol Propionate | 37 | $1,734 |
| Raloxifene Hcl | 32 | $1,477 |
| Medroxyprogesterone Acetate | 23 | $657 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 21 | $355 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 17 | $246 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $923 | $70,49673 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $257 | $43,88948 claims |
| PfizerPremarin, Prempro | $570 | $35,93279 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Other obstetrics & gynecology in Honesdale
- Marvin KalaferJenkintown$4.6M
- Catherine ChappellPittsburgh$4.3M
- Stephen KlaskoPhiladelphia$2.2M
- Robert EdwardsPittsburgh$1.9M
- Stephanie SoberPhiladelphia$1.8M
- Michael ScutellaErie$1.7M
- Sarah TaylorPittsburgh$1.3M
- Andrea RoePhiladelphia$925K
- Beatrice ChenPittsburgh$549K
- Courtney SchreiberPhiladelphia$519K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.